COX4I2 and bone neoplasm: Clinically, these findings have dual implications: firstly, COX4I2 may serve as a prognostic biomarker for patients with bone tumors; secondly, targeting COX4I2 or its exosomal packaging and delivery pathways could potentially enhance the efficacy of ferroptosis-based therapies.